The Food and Drug Administration (FDA) today approved the first generic versions of Levaquin (levofloxacin), an antibiotic approved to treat certain infections in people ages 18 and older.
Levofloxacin is used to treat mild, moderate, or severe bacterial infections of the skin, sinuses, kidneys, bladder, and prostate caused by specific germs. It also is used to treat certain bacterial infections that cause bronchitis or pneumonia, and to treat those exposed to inhalational anthrax.
"Generic drugs are important options that allow greater access to health care for Americans," says Keith Webber, PhD, deputy director of the Office of Pharmaceutical Science in the FDAs Center for Drug Evaluation and Research. "FDA-approved generic drugs must meet rigorous standards and are required to be of high quality so that people can be assured that their medications will act the same in the body as the brand-name product."
Generic tablet, oral solution, and injectable solution dosage forms of levofloxacin have been approved. The following 12 manufacturers applications for generic levofloxacin have been approved:
- Akorn Inc.
- Aurobindo Pharma Ltd.
- Dr. Reddys Laboratories Ltd.
- Glenmark Generics Ltd.
- Hi-Tech Pharmacal Co. Inc.
- Lupin Ltd.
- Mylan Pharmaceuticals Inc.
- Sagent Strides LLC
- Sandoz Inc.
- Teva Pharmaceuticals USA
- Torrent Pharmaceuticals Ltd.
- Wockhardt Ltd.
Levofloxacin belongs to a class of drugs called fluoroquinolones. All fluoroquinolones have a boxed warning alerting prescribers and patients that these products are associated with an increased risk of tendinitis and tendon rupture. The risk is greater in older people, especially in those older than 60, in patients taking corticosteroid drugs, and in those with kidney, heart, or lung transplants. The boxed warning also contains an alert that the drug may worsen muscle weakness in people with myasthenia gravis, a chronic autoimmune neuromuscular disease.
Levofloxacin must be dispensed with a patient Medication Guide that describes the drugs uses and warnings.
Implementing Infection Control Protocols in Turbomachinery Manufacturing Environments
December 8th 2023Explore the challenges and innovations in infection control protocols for turbomachinery manufacturing. Discover the role of automation, IoT, and employee training in safeguarding health and productivity.
Chief Infection Prevention Officer: Leading the Way Into the Future
December 7th 2023The role and responsibility of executive-level oversight in infection prevention is growing. Expertise, determination, consistency, and sustainability bring value to reducing healthcare–associated infections, preventing harm, and supporting a safe workplace.